-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
-
-
-
-
-
15,661 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

